Janssen
NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression
September 3, 2020Sales and Marketing Janssen, Spravato, depression, pharma
NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …
FDA expands Stelara indication to cover paediatric plaque psoriasis
July 31, 2020Medical Communications, Sales and Marketing Janssen, Stelara, pharma, plaque psoriasis
Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …
Emergent forges five-year partnership to produce one billion doses of Janssen’s COVID-19 vaccine
July 7, 2020Manufacturing and Production COVID-19, Emergent, J&J, JJ, Janssen, coronavirus
As many pharma firms move to secure upscaled manufacturing capacity for their potential COVID-19 vaccines, Johnson & Johnson’s Janssen has …
Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says
June 15, 2020Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis
Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual …
Janssen’s Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies
June 4, 2020Research and Development Janssen, Tremfya, psoriatic arthritis
Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in …
100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows
May 14, 2020Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma
Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell …
NICE backtracks to approve Janssen’s Stelara in ulcerative colitis
April 28, 2020Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis
NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …
Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes
April 15, 2020Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma
Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …
New Johnson & Johnson study aiming to add stroke detection to Apple Watch
February 26, 2020Research and Development Apple, Janssen, Johnson & Johnson, apple watch, iphone, stroke
Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection. It …
Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease
February 18, 2020Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …
Janssen’s Erleada expanded in Europe to cover metastatic hormone-sensitive prostate cancer
January 29, 2020Research and Development, Sales and Marketing Erleada, Europe, Janssen, pharma
Janssen’s Erleada (apalutamide) has secured expanded authorisation from the European Commission (EC), approving its label to include the treatment of …
NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression
January 28, 2020Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression
Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …
European Commission expands Stelara for paediatric moderate to severe plaque psoriasis
January 24, 2020Research and Development Europe, Janssen, Stelara, pharma
Janssen’s Stelara (ustekinumab) has seen its label expanded in Europe to include the treatment of moderate to severe plaque psoriasis …
European Commission authorises Janssen’s anti-depressant Spravato
December 23, 2019Sales and Marketing Janssen, MDD, Nasal Spray, TRD, depression, mental health
The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that …
Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma
Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
